

ATONCO ANNOUNCES THE APPOINTMENT OF SYLVAIN FANIER AS NEW PRESIDENT OF ATONCO

Atonco announced today that Sylvain Fanier, Msc. EMBA, will succeed Professor Jean-François Chatal as President as of March 16, 2020.

Mr. Fanier has spent his career overseeing and leading the development of several global medical innovations in the healthcare industry. He brings to the company leadership in strategy, global business perspective and financing acquired over the past 30 years in large corporations such as Johnson & Johnson and CR Bard and in medical startups. Specialized in disruptive medical innovation, he has accompanied the success of innovative companies such as Lemerpax, Cardioinsight, Sonoscanner, Soundbite Medical Solutions, Surgivisio and Med-Innov through his consulting company, Novariver.

He obtained a bachelor's degree in biochemistry and a master's degree in biology with a physiology option from the Paul Sabatier University in Toulouse. He also holds an EMBA from ESSEC, Paris, France.

Sylvain is a member of the Board of Directors of Soundbite Medical Solutions Inc. (Montreal, Canada), and Ecential Robotics SAS (Grenoble, France).

Jean-Pierre Cabocel, Chairman of the Board of Directors, said: "I am delighted that Sylvain is taking on the position of President. I am confident that he will play a key role in the development and success of Atonco. I am also delighted that Jean-François Chatal will remain involved in our developments as co-founder and Medical Director.

"It is an honor to be named President of Atonco," added Mr. Fanier. "With the support of the management team and talented and experienced advisors, we will optimize our development, strengthen our organization and partnerships to ensure the growth of Atonco."

About ATONCO

ATONCO is a privately held French company developing molecularly targeted radiopharmaceuticals for oncology applications. Originating from the world-class nuclear medicine cluster in Nantes, ATONCO and its academic partners are committed to the clinical use of alpha-emitting radionuclides, in particular astatine-211 (^{211}At).

For more information, visit www.atonco-pharma.com

Important Information This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States, or in any other jurisdiction in which such an offer would be illegal. The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933 (the "US Securities Act"), or under the securities laws of any state or other jurisdiction of the United States and may not be offered or sold within the United States, unless the securities have been registered under the US Securities Act or an exemption from the registration requirements of the US Securities Act is available